<DOC>
	<DOCNO>NCT01652027</DOCNO>
	<brief_summary>Hemophilia A congenital bleeding disorder cause deficiency factor VIII ( FVIII ) treat replacement therapy FVIII concentrate . Approximately 30 % people severe hemophilia A develop neutralize antibody , call FVIII inhibitor , interfere function FVIII concentrate . The reason , , people severe hemophilia A develop inhibitor incompletely understood . Understanding individual environmental risk factor important able prevent possibly treat inhibitor . This study look individual treatment characteristic baby severe hemophilia A yet receive treatment FVIII ( call Previously Untreated Patients , PUPS ) . Subjects study ask provide diary treatment , medication , illness . Treatment direct subject ' physician , subject receive Advate , third-generation recombinant FVIII product . Subjects blood drawn laboratory test , include study immune system genetic study FVIII mutation , 7-9 day first treatment FVIII , 5 day ( +/-2 day ) 5th , 10th , 20th , 30th , 40th , 50th day treatment FVIII ( exposure day ) . The duration study first 50 treatment 3 year , whichever come first .</brief_summary>
	<brief_title>Hemophilia Inhibitor Previously Untreated Patient Study</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<criteria>Severe hemophilia A FVIII activity &lt; 1 % normal Weight &gt; 3.5 kg time baseline study evaluation Informed consent , approve appropriate Institutional Review Board/Independent Ethics Committee , administer , sign , date Prior exposure clot factor concentrate blood product Other chronic disease Currently participate another investigational drug study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>FVIII inhibitor</keyword>
</DOC>